- Saturday, April 20, 2024
By: Radhakrishna N S
GlaxoSmithKline Plc and Tesaro Inc have announced on Monday (3) that the companies have entered into a definitive agreement pursuant to which GSK will acquire Tesaro, an oncology-focused company based in Waltham, Massachusetts for approximately four billion pounds. The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro is a commercial-stage biopharmaceutical company, with a major marketed product, zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit…
You do not have access to this content. You need to subscribe.
